Genmab — August 2023
-
New Genmab trial: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT06018129
-
Brief Summary:
The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections
-
Det var en dyr lukkeauktion idag

-
Absolut - men lå i + på porteføljen kl. 16:55. - og endte i -0,18

-
Nå, men hvorom alting er: Jeg fornemmer, at vi alle også overlever idag

-
Øhhhh @Bulder 17:17 : Jeg ville godt have haft nogle af de aktier i Novo, der er i + idag

-
Ok
troede, du var gået i bear 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
CD3xCD30